Fischer Medical Ventures brings AI-powered drug discovery platform ‘Vecura’ to India

MUMBAI: Fischer Medical Ventures Limited (FMVL) has announced the introduction of Vecura, an advanced artificial intelligence-enabled molecular research platform, to India, marking a significant step toward accelerating pharmaceutical research, computational biology and AI-driven drug discovery in the country.

The strategic collaboration aims to make cutting-edge molecular analysis tools accessible to pharmaceutical companies, biotechnology firms, research institutions and academic organizations, enabling faster discovery of new therapeutic molecules while reducing the cost and time involved in early-stage research.

According to the company, Vecura leverages artificial intelligence to simulate molecular behaviour, predict compound interactions and support high-throughput computational analysis, helping researchers identify promising drug candidates with greater speed and precision.

Accelerating Drug Discovery Through AI

Drug discovery has traditionally been a lengthy and expensive process, often taking years of laboratory experimentation before a viable therapeutic candidate is identified.

Vecura seeks to transform this process by enabling researchers to:

• Simulate molecular interactions digitally.
• Identify promising biological targets.
• Predict molecular properties.
• Screen thousands of compounds computationally.
• Reduce dependence on extensive laboratory experimentation.

By combining computational biology with AI, the platform is expected to significantly improve research productivity while enabling scientists to focus laboratory efforts on the most promising drug candidates.

Bringing Scientific Validation to Ayurveda

One of the most distinctive aspects of the initiative is its focus on integrating Ayurveda with modern pharmaceutical research.

India possesses one of the world’s richest repositories of medicinal plants and traditional therapeutic knowledge. However, much of this knowledge remains scientifically underexplored using contemporary molecular research techniques.

FMVL believes AI can bridge this gap by enabling researchers to identify bioactive molecules within Ayurvedic formulations, understand their mechanisms of action and validate their therapeutic potential through computational analysis.

The company says this convergence of Ayurveda, artificial intelligence and computational biology could lead to the development of scientifically validated plant-derived therapeutics with applications in both domestic and international healthcare markets.

Strengthening India’s Innovation Ecosystem

India is already one of the world’s leading pharmaceutical manufacturing hubs, particularly in generic medicines and formulation development.

However, the company believes there remains considerable opportunity for the country to strengthen its capabilities in:

• Novel drug discovery
• AI-led pharmaceutical research
• Molecular innovation
• Precision medicine
• Computational biology

Vecura is expected to support this transition by enabling researchers to accelerate target identification, molecular optimisation and compound screening, thereby reducing research timelines and improving innovation efficiency.

Benefits for Pharma and Biotechnology

According to FMVL, the platform offers several potential advantages for India’s pharmaceutical ecosystem, including:

• Faster identification of promising therapeutic molecules.
• Reduced research costs through AI-based computational screening.
• Improved collaboration between academia and industry.
• Scientific validation of traditional medicinal knowledge.
• Enhanced global competitiveness in innovation-driven pharmaceutical research.

The company believes the platform can help India move beyond its traditional manufacturing strengths and emerge as a leader in next-generation drug discovery.

AI at the Core of Future Healthcare

Vecura has been developed as an AI-enabled molecular research platform capable of supporting researchers across multiple therapeutic domains, including natural product research, precision medicine and plant-derived molecule discovery.

Its ability to model molecular behaviour digitally enables scientists to move from hypothesis generation to validation more efficiently, reducing the experimental burden associated with conventional discovery methods.

FMVL says the platform aligns with the broader global shift toward integrating artificial intelligence, software and computational biology into pharmaceutical research and development.

Positioning India for the Next Wave of Healthcare Innovation

With countries around the world increasingly adopting AI-powered research platforms, FMVL believes India has the opportunity to become a global leader in AI-enabled healthcare innovation.

By introducing Vecura, the company aims to build a future-ready healthcare ecosystem that combines diagnostics, computational research and data-driven therapeutic development while fostering collaboration among pharmaceutical companies, biotechnology startups, universities and research institutions.

The company said it looks forward to partnering with stakeholders across the healthcare and life sciences sectors to strengthen India’s capabilities in AI-powered molecular research and accelerate the discovery of innovative therapies.